Nt-probnp-based screening

Intervention

1 paper2 findings

  • 1 lab in 1 country
  • Funder: AstraZeneca
  • 2 of 2 findings with company ties
  • Human trial1

Outcomes

2

Sodium-glucose cotransporter 2 inhibitors

upin humans1

1 study
  1. Nt-probnp-based screening increases sodium-glucose cotransporter 2 inhibitors in humans (24% to 39%).

    Human trialtype 1 or type 2 diabetes and at least 1 additional heart failure risk factorn = 354

    Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)

    Journal of the American College of Cardiology11 Aug 2026

More on Sodium-glucose cotransporter 2 inhibitors

Heart failure

upin humans1

1 study
  1. Nt-probnp-based screening increases heart failure in humans (OR: 58; 95% CI: 14-236).

    Human trialtype 1 or type 2 diabetes and at least 1 additional heart failure risk factor6 monthsn = 706

    Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)

    Journal of the American College of Cardiology11 Aug 2026

More on Heart failure

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01 in 12 months